SCP
NBIX icon

Sivia Capital Partners’s Neurocrine Biosciences NBIX Stock Holding History

Sivia Capital Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62M Buy
9,594
+6,345
+195% +$941K 0.2% 112
2026
Q1 		$428K Sell
3,249
-3,851
-54% -$511K 0.08% 287
2025
Q4 		$1.01M Buy
7,100
+3,276
+86% +$475K 0.2% 110
2025
Q3 		$537K Buy
3,824
+2,112
+123% +$286K 0.15% 147
2025
Q2 		$215K Buy
+1,712
New +$196K 0.07% 387

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AB
Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

Sivia Capital Partners's NBIX Position: Q2 2026 in Review

Sivia Capital Partners increased its Neurocrine Biosciences (NBIX) stake by 195% in Q2 2026, buying an estimated $941K and bringing the position to 9,594 shares worth $1.62M. The position accounts for 0.2% of the portfolio, ranked #112.

Sivia Capital Partners first reported a position in NBIX in Q2 2025 and has held it in 5 quarters since. 166 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Sivia Capital Partners held 9,594 shares of Neurocrine Biosciences worth $1.62M as of Q2 2026.
  • Sivia Capital Partners bought 6,345 Neurocrine Biosciences shares in Q2 2026, an estimated $941K.
  • Neurocrine Biosciences made up 0.2% of Sivia Capital Partners's portfolio in Q2 2026, its #112 holding.
  • Sivia Capital Partners first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 166 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Sivia Capital Partners's 13F filing for Q2 2026, filed 23 Jul 2026.